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Abstract: The pathogenesis of asthma and chronic obstructive pulmonary disease (COPD) 
has been claimed to be attributable to increased systemic and local oxidative stress. Detection 
of the oxidant burden and evaluation of their progression and phenotypes by oxidant biomark-
ers have proved challenging and difﬁ  cult. A large number of asthmatics are cigarette smokers 
and smoke itself contains oxidants complicating further the use of oxidant biomarkers. One of 
the most widely used oxidant markers in asthma is exhaled nitric oxide (NO), which plays an 
important role in the pathogenesis of asthma and disease monitoring. Another oxidant marker 
that has been widely investigated in COPD is 8-isoprostane, but it is probably not capable of 
differentiating asthma from COPD, or even sensitive in the early assessment of these diseases. 
None of the current biomarkers have been shown to be better than exhaled NO in asthma. 
There is a need to identify new biomarkers for obstructive airway diseases, especially their 
differential diagnosis. A comprehensive evaluation of oxidant markers and their combinations 
will be presented in this review. In brief, it seems that additional analyses utilizing powerful 
tools such as genomics, metabolomics, lipidomics, and proteomics will be required to improve 
the speciﬁ  city and sensitivity of the next generation of biomarkers.
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Asthma and chronic obstructive pulmonary disease (COPD) are diseases with differ-
ent physiological and anatomical features. However, a signiﬁ  cant number of patients 
suffering from these diseases exhibit symptoms and signs which are associated with 
both conditions. Markers of the elevated oxidant burden have been detected in both 
of these disorders. This degree of overlap between asthma and COPD has proved 
to be especially important in smoking asthmatics, patients who have often been 
excluded from asthma trials and investigations. Oxidant markers are under intensive 
investigation as ways of assuring the early detection and monitoring of asthma and 
COPD, for the differentiation of the disease from the condition of “healthy smokers”, 
and also for the evaluation of the COPD phenotypes and their progression. This review 
will critically review potential markers that reﬂ  ect oxidative stress in the airways of 
patients with asthma and COPD in exhaled air, exhaled breath condensate (EBC) and 
induced sputum. In addition, markers in bronchoalveolar lavage (BAL) will also be 
brieﬂ  y surveyed, even though the technique, ie, ﬁ  breoptic bronchoscopy is an inva-
sive technique used in the investigation of lung inﬂ  ammation and the evaluation of 
the oxidant burden. In this review, we will also discuss the pros and cons of various 
noninvasive biological samples for assessing the oxidant burden in the airways, and 
then speculate on the possibilities of using the existing and new oxidant markers, International Journal of COPD 2008:3(4) 586
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their potential combinations, and make suggestions for 
future investigations.
Clinical and inﬂ  ammatory features 
of asthma and COPD
According to the Global Initiative for Asthma Guidelines 
(GINA 2002) asthma is deﬁ  ned as a chronic inﬂ  ammatory 
disorder of the airways in which many cells and cellular 
elements play a role. The chronic inﬂ  ammation evokes 
an associated increase in airway hyperresponsiveness that 
leads to recurrent episodes of wheezing, breathlessness, 
chest tightness, and coughing, particularly at night or in 
the early morning. These episodes are usually associated 
with widespread but variable airﬂ  ow obstruction that is 
often reversible, either spontaneously or with treatment. In 
the Global Initiative for Chronic Obstructive Lung Disease 
Guidelines (GOLD 2002; Rabe et al 2007), COPD is deﬁ  ned 
as a preventable and treatable disease state characterized by 
airﬂ  ow limitation that is not fully reversible. COPD is also 
associated with emphysematous parenchymal destruction, 
variable loss of lung elastic recoil, and abnormalities in gas 
diffusion. The physiological ﬁ  ndings in individual patients 
with either clinical asthma or COPD, when isolated from the 
context of their environmental and clinical histories, may not 
allow the physician to distinguish between the conditions 
(Boulet et al 1998; Fabbri et al 2003). This inability to clearly 
differentiate these conditions can lead to frustration in both 
the clinic and research settings.
There are a large number of studies and reviews on the 
inﬂ  ammatory proﬁ  le in asthma and COPD (Kirby et al 1987; 
Walters and Gardiner 1992; Keatings and Barnes 1997; 
Chanez et al 1999; van Aalderen et al 1999; Gibson et al 
1999; Jeffery 1999; Saetta 1999; NHLBI/WHO 2002; Loh 
et al 2005; Tetley 2005). Airway inﬂ  ammation is present in 
all forms of asthma, even in mild (Battaglia et al 2005) and 
asymptomatic cases (Bousquet et al 2000; Montuschi et al 
2004) and it can be detected in both central and peripheral 
airways (Hamid et al 1997) in asthma. There is a strong 
association between fractional exhaled nitric oxide (FeNO) 
and skin prick test scores, total immunoglobulin E (IgE) 
(Ho et al 2000) and blood eosinophilia (Silvestri et al 1999). 
In contrast, COPD is a disease characterized by airway 
inﬂ  ammation with neutrophil predominance (Bosken et al 
1992), and periods of acute exacerbations (Fletcher and 
Peto 1977) with further increased airway inﬂ  ammation and 
worsening of lung function (Gompertz et al 2001). Cigarette 
smoking is the major risk factor for development of COPD, 
and smoking cessation is at present the only effective way 
to slow down the disease progression (Culpitt and Rogers 
2000; Scanlon et al 2000). COPD exacerbations are often 
triggered by viral or bacterial infections consisting not only 
of increased numbers of neutrophils, but also of eosinophils 
and activated macrophages in the airways (Rahman and 
MacNee 2000; Saetta et al 2001). Neutrophil accumulation 
on the other hand is one typical feature that is seen in asthma 
exacerbation (Fahy et al 1995a; Kim et al 2000). There is 
overlap not only in the inﬂ  ammatory proﬁ  le but also in the 
oxidant markers, especially in acute asthma and COPD exac-
erbations. The present review focuses on oxidant markers, 
but the numbers of certain inﬂ  ammatory cells and the levels 
of cytokines have also been found to be signiﬁ  cantly cor-
related with oxidant markers in the airways of patients with 
asthma and COPD.
The differential diagnosis of asthma and COPD is espe-
cially difﬁ  cult in smoking individuals. Cigarette smoke 
activates macrophages and polymorphonuclear leukocytes 
to produce more reactive oxygen species (ROS) and this, in 
turn, leads to the recruitment of leukocytes into the airways 
(Niewoehner et al 1974; Hoidal and Niewoehner 1982). 
Since symptoms and lung function tests are indirect methods 
to assess the disease severity both in asthma and COPD, they 
may not reveal the extent of the underlying airway pathology. 
Smoking alone has multiple effects on the airways and there 
is a need to clearly differentiate the effects of smoking from 
the disease and its progression, a topic that has not been 
systematically evaluated.
Biomarker requirements in asthma 
and COPD differentiation
Oxidative stress has been claimed to be involved in the devel-
opment of both asthma and COPD (Kharitonov and Barnes 
2001b; Montuschi et al 2004; Kinnula 2005a; Rahman and 
Adcock 2006). There is more than one phenotype in COPD 
and asthma and these phenotype subtypes have not been sepa-
rately evaluated with respect to the proﬁ  les of the oxidative 
stress burden are inﬂ  uenced in the different phenotypes. Cur-
rently, there is plenty of research being conducted to develop 
noninvasive tools for disease detection and follow-up, eg, 
easy-to-use devices and sensitive and speciﬁ  c technologies. 
Only practical and readily reproducible, completely nonin-
vasive techniques offer these possibilities. The biomarkers 
themselves must possess certain characteristics if they are to 
be of any use. In addition to sensitivity and speciﬁ  city, a bio-
marker needs to be stable, with minimal diurnal or day-to-day 
variability, and it should be easy to access and analyse, and 
still be cost-effective. Furthermore, the biomarkers should be International Journal of COPD 2008:3(4) 587
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useful for early diagnostics, differential diagnosis, response 
to therapy, and for the evaluation of disease progression. It is 
unlikely that any single biomarker can ever possess all these 
characteristics. Instead, panels or various combinations of 
biomarkers are needed. These panels could consist of dif-
ferent components if they are used for either the differential 
diagnosis or for the assessment of disease severity and its 
progression.
Oxidative stress in the airways 
in asthma and COPD
ROS and reactive nitrogen species (RNS) are produced 
endogenously by several cell types including activated 
inﬂ  ammatory and structural cells, the most potent generators 
of these species being eosinophils and neutrophils, ie, cells 
that are abundant both in asthma and COPD (Kinnula 2005b). 
The burden of ROS/RNS is further increased by exogenous 
factors, mostly by environmental agents and cigarette smoke. 
One puff of cigarette smoke contains billions of free radicals 
(Church and Pryor 1985). These ROS, present both in asthma 
and smoking-related airway diseases, have multiple effects 
including activation of proteases, mucus secretion, airway 
smooth muscle contraction, airway hyperresponsiveness, 
and transcription of many inﬂ  ammatory genes (Kawikova 
et al 1996; Rahman and MacNee 1998; Paredi et al 2002; 
Wood et al 2003).
Oxidants present in cigarette smoke stimulate alveolar 
macrophages to further produce ROS, such as superoxide 
radical (O2
• −), hydroxyl radical (•OH), and hydrogen peroxide 
(H2O2), leading to release of a number of mediators, some of 
which attract neutrophils and other inﬂ  ammatory cells into 
the lungs of COPD patients (GOLD 2002). Activated inﬂ  am-
matory cells generate more ROS via the NADPH oxidase 
system. Similarly, increased levels of xanthine oxidase, found 
in cell free bronchoalveolar lavage (BAL) ﬂ  uid and plasma 
from COPD patients, can elevate O2
• − and lipid peroxide lev-
els (GOLD 2002). Thus, oxidants may be triggering factors 
for the inﬂ  ammation seen in COPD. Asthma on the other 
hand, may be triggered by viral infections, air pollutants such 
as ozone and cigarette smoke, and other cellular mediators 
(Dworski 2000). These agents cause inﬂ  ux and activation of 
inﬂ  ammatory cells (macrophages, neutrophils, eosinophils, 
lymphocytes, and mast cells) which subsequently evoke the 
generation of inﬂ  ammatory mediators. All of these converge 
to produce ROS which in turn leads to an increased inﬂ  am-
matory response, producing asthma-like symptoms. Oxida-
tive stress is associated with activation of cytokines/growth 
factors but in these same conditions activated inﬂ  ammatory 
cells produce large amounts of ROS into the airways. Thereby 
it can be postulated that symptoms are not only linked to the 
airway inﬂ  ammation but also to the oxidant burden in the 
airways both in asthma and COPD. ROS have been shown 
to be associated with the pathogenesis of asthma by evoking 
bronchial hyperreactivity as well as directly stimulating 
histamine release from mast cells and mucus secretion from 
airway epithelial cells (Dworski 2000). Thus, while oxida-
tive stress due to smoking is a direct causative factor for 
COPD leading to a further elevation of oxidative stress, it is 
usually a secondary effect in asthma subsequent to a prior 
antigenic/allergic challenge of immune cells in the lungs.
Once oxidative stress reaches a critical level, it is difﬁ  cult 
to demarcate between the two diseases asthma and COPD. 
However, site of afﬂ  iction, the cells involved and the pattern 
of response by the lungs can help in differentiating these two 
diseases. In COPD, the major site of attack is the alveolar 
space. Inﬂ  ammatory cells themselves become compartmen-
talized, for example, neutrophils are mainly located in the 
lumen of the airways and macrophages accumulate in the 
interstitium in COPD. COPD has been strongly associated 
with an accumulation of inﬂ  ammatory mucous exudates in 
the lumen of the small airways (Saetta et al 2001). In COPD, 
oxidant stress occurs in small airways, lung parenchyma, and 
the alveolar regions. In asthma, the larger airways are the 
major site of action, with the characteristic signs being revers-
ible airﬂ  ow obstruction, airway hyper-responsiveness/hyper-
reactivity, and chronic inflammation attributable to an 
inﬂ  ux of eosinophils and activation of inﬂ  ammatory cells 
such as macrophages, neutrophils, lymphocytes, and mast 
cells. Airway smooth muscle contraction, increased airway 
reactivity and secretions, increased vascular permeability 
and increased generation of chemoattractants are the major 
features of an asthmatic response (Hamid et al 1997). Hence, 
compartmentation of different inﬂ  ammatory cells in the 
lungs may help clarify the type of oxidative stress response 
in asthma and COPD.
Many oxidants (such as O2
• − and •OH) are unstable and 
have very short half lives, and are therefore difﬁ  cult to mea-
sure. Hydrogen peroxide (H2O2) is formed from superoxide 
(mainly by inﬂ  ammatory cells including both eosinophils 
and neutrophils) and is directly involved in many reactions. 
NADPH oxidase is one of the key superoxide generating 
enzymes that is expressed both in phagocytic and nonphago-
cytic cells (Jones et al 2000). NADPH oxidases (NOXs) and 
dual oxidases (DUOXs) may function as potent ROS genera-
tors in inﬂ  ammatory conditions of human airways, but little is 
known about their role in asthma or COPD. Myeloperoxidase International Journal of COPD 2008:3(4) 588
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(MPO) is abundantly present in neutrophils and catalyses the 
reaction of H2O2 with chloride forming hypochlorous acid 
(HOCl). Eosinophil peroxidase (EPO) catalyses the reaction 
of H2O2 with bromide within eosinophils forming hypobro-
mous acid (HOBr), which is released during the respiratory 
burst (Wu et al 2000; van Dalen and Kettle 2001; Aldridge 
et al 2002). Endogenous NO is derived from L-arginine by at 
least three different isoforms of NOS (Nathan and Xie 1994). 
Two of these are expressed constitutively (NOS1, NOS3) 
while the inducible form of  NOS (iNOS, NOS2) can be acti-
vated by inﬂ  ammatory cytokines. Inducible NOS generates 
the majority of the NO encountered in inﬂ  ammatory states 
since the enzyme is induced by cytokines and is expressed in 
inﬂ  ammatory cells (like neutrophils) as well as in nonphago-
cytic cells (like alveolar/bronchial epithelial and endothelial 
cells) (Barnes and Belvisi 1993). Once ROS are generated, 
they rapidly attack membrane lipids leading to the genera-
tion of lipid peroxidation products such as isoprostanoids, 
malondialdehyde, and 4-hydroxy-2-nonenal (4-HNE). 
These markers have been widely used in the assessment of 
oxidative stress in the lung (Kharitonov and Barnes 2001b; 
Paredi et al 2002), but a major limitation with most of these 
end products is their poor speciﬁ  city and reproducibility in 
different diseases that are related to oxidative stress. Each of 
these markers will be discussed below in the context of their 
use in asthma and COPD diagnosis and differentiation.
The antioxidant machinery of the lung is complex, 
containing a variety of low molecular weight antioxidants, 
metal binding proteins, mucus glycoproteins, and several 
speciﬁ  c antioxidant enzymes (Kinnula et al 1995; Kinnula 
and Crapo 2003; Kinnula 2005a, 2005b). It is apparent that 
in oxidant-mediated airway diseases, ROS gradually over-
whelm host antioxidant defenses, leading to the ultimate 
oxidant-mediated cell and tissue damage (Kinnula 2005b). 
Total antioxidant capacity of plasma is decreased in smokers 
and patients with asthma and COPD (Rahman et al 1996). It 
is interesting to note that the decrease in antioxidant capacity 
in smokers occurs transiently during smoking and resolves 
rapidly after smoking cessation. The depletion of total anti-
oxidant capacity in smokers is associated with decreased 
levels of plasma antioxidants eg, ascorbic acid, vitamin E, 
β-carotene, and selenium (Rahman et al 1996). The deple-
tion of antioxidants may thus be a reﬂ  ection of ongoing 
oxidative stress due to underlying inﬂ  ammation in these 
diseases. The thiol antioxidant glutathione (GSH) and its key 
biosynthesizing enzyme, glutamate cysteine ligase (GCL), 
are decreased in the airways, and in macrophages of smokers 
compared to nonsmokers (Harju et al 2002a). However, 
very little is known about antioxidant enzymes/antioxidant 
biomarkers in asthma and COPD or their association with 
disease severity or progression. It is likely that there are no 
speciﬁ  c changes in the antioxidant systems during the early 
phases of airway diseases, instead their changes may reﬂ  ect 
disease severity.
Noninvasive techniques to detect 
airway oxidative stress: Pros and 
cons
Exhaled air
Even though several methods have been developed to 
measure oxidant related damage/burden in cells, tissues, 
and body ﬂ  uids, there has been great interest in the analysis 
of exhaled air since this is a totally noninvasive technique. 
Standardized measurements of fractional exhaled nitric 
oxide (FeNO) provide a noninvasive and reproducible means 
for monitoring asthma (Kharitonov et al 1997; Anonymous 
1999; Kharitonov 2004). A wide range of commercially 
available analyzers exist, which decreases the cost of 
individual measurements. Persistent generation of oxygen 
radicals in the body leads to the formation of other com-
pounds, which can also be measured from the exhaled air; 
these include carbon monoxide (CO) which is formed by 
enzymatic degradation of heme and nonheme-related release 
(Kharitonov and Barnes 2001b) and hydrocarbons such as 
volatile organic compounds (VOC), which are nonspeciﬁ  c 
markers of lipid peroxidation (Kneepkens et al 1994). The 
activation of inﬂ  ammatory cells, including macrophages, 
eosinophils, and neutrophils, results in increased produc-
tion of O2
•¯ and the subsequent formation of H2O2. H2O2 has 
been proposed to be a potential marker of oxidative stress 
in the lungs and this mediator has been evaluated in many 
investigations (Kharitonov 2004). In summary, exhaled air 
is one of the most promising ways for the assessment of 
oxidative stress; it has many advantages and the technology 
is now being developed so that there are portable devices at 
a relatively low cost. There exists, in addition, a good con-
sensus on the signiﬁ  cance of some oxidant markers (such as 
FeNO) that are detectable from the exhaled air.
Exhaled breath condensate
Exhaled breath condensate (EBC) is condensed from 
water but also contains droplets that carry solute from the 
lower respiratory tract. The collection of EBC by cooling 
exhaled air has several advantages compared to many other 
methods of sampling the airspaces. It is simple to con-
duct, noninvasive, and easily repeatable (Kharitonov and International Journal of COPD 2008:3(4) 589
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Barnes 2001b). It does not cause airway inﬂ  ammation, nor 
does it have any signiﬁ  cant inﬂ  uence on airway function 
(Baraldi et al 2003c), making repeated sampling possible 
(Kharitonov and Barnes 2001b; Kharitonov and Barnes 
2002). EBC collection is relatively inexpensive and does 
not include any appreciable discomfort or risk to the sub-
ject. Moreover, EBC collection is also suitable for children, 
because it is effort-independent. It can even be applied in 
mechanically ventilated patients. The collection of EBC 
has been described in detail (Rahman and Biswas 2004; 
Horvath et al 2005). Many nonvolatile molecules (media-
tors, oxidation, and nitration products) can be measured in 
EBC, with 8-isoprostane being the most widely measured of 
the oxidant markers found in EBC (Kharitonov and Barnes 
2001b). There is accumulating evidence suggesting that 
the abnormalities in biomarkers present in EBC may reﬂ  ect 
the degree of asthma and COPD severity better than can be 
assessed by either spirometry or symptoms (Montuschi et al 
1999; Kharitonov and Barnes 2001b).
EBC mirrors the composition of the extracellular lining 
ﬂ  uid (ELF) but the major drawbacks are saliva contamination, 
sample dilution, and high individual variability. There exists 
a lack of evidence of the primary origin of the aerosol par-
ticles that carry the droplets from the lower respiratory tract 
(Van Hoydonck et al 2004). Dilution of EBC can be corrected 
by measuring the level of urea and/or electrolytes derived 
from ELF. Other confounding factors include consumption 
of alcohol, diets with variable amounts of antioxidants, 
smoking, subclinical lung diseases which have not been 
clinically manifested, and differences in the collection of the 
samples and their storage. Signiﬁ  cant salivary contamination 
can be excluded by measuring the amylase concentrations 
in samples (Kharitonov and Barnes 2001b), but uncertainty 
still exists with respect to the nasal contamination. Recom-
mendations for EBC have been formulated by the European 
Respiratory Society/American Thoracic Society task force, 
but these recommendations also emphasized the difﬁ  culties 
encountered in the sampling and analysis of EBC (Horvath 
et al 2005). To date the majority of the analyses conducted 
in EBC have involved spectrophotometry and enzyme 
immunoassays, as well as sophisticated analytical techniques 
such as gas chromatography/mass spectrometry (GC/MS) 
or high-performance liquid chromatography (HPLC). Spin 
trapping is one of the most direct methods available for the 
assessment of highly reactive free radicals/oxidants. These 
latter techniques require special expertise and as far as we are 
aware, they have not been used for assaying EBC in clinical 
settings. In summary, the collection of EBC is easy and it is 
therefore promising for the evaluation of oxidant markers. 
Major limitations in the EBC include the plethora of potential 
markers that cannot be reliably or easily analyzed in these 
highly diluted samples.
Induced sputum
Induced sputum represents a nearly noninvasive technique; 
the collection of induced sputum by hypertonic saline has 
been shown to be a safe (Vlachos-Mayer et al 2000; Wark 
et al 2001), effective, and relatively reproducible (Pizzichini 
et al 1996; Ward et al 1999; Fahy et al 2001; Simpson et al 
2005) method for investigating airway diseases in adults 
(Pizzichini et al 1998; Wark et al 2002; Wilson et al 2006) 
and children over 6 years of age (Twaddell et al 1996; Norzila 
et al 2000). Induced sputum samples provide information 
about both inﬂ  ammatory mediators and the inﬂ  ammatory 
cells present in the airways (Simpson et al 2005) and they 
are believed to accurately mirror conditions at the site of 
oxidative damage (Kelly et al 1999).
However, there is some evidence that induced sputum 
is sampled predominantly from the large airways (Alexis 
et al 2001) and may not reflect the peripheral airways. 
Sputum induction is often difﬁ  cult to accomplish, involves 
some discomfort to the patient, induces an inﬂ  ammatory 
response (Nightingale et al 1998), and may induce cough-
ing and bronchoconstriction in patients with COPD (Rytila 
et al 2000; Taube et al 2001) and in asthma (Smith and 
Anderson 1990; Antczak et al 2005), despite pretreatment 
with an inhaled beta2-agonist (Rytila et al 2000; Paggiaro 
et al 2002). The processing of the sputum sample needs to 
be immediate and requires expertise and this signiﬁ  cantly 
limits its use in routine clinical practice. Sampling cannot 
be repeated within a short period of time, and the technique 
itself may induce an inﬂ  ammatory response, which may 
persist for 24 h (Nightingale et al 1998; Holz et al 1998). 
Contamination of sputum samples by saliva may lead to 
reduced mediator concentrations, although differential cell 
counts remain relatively unchanged (Simpson et al 2004). 
On the other hand, several markers are relatively similar in 
the induced sputum and BAL and the technique of collect-
ing induced sputum is much less invasive than ﬁ  breoptic 
bronchoscopy (Fahy et al 1995b). Overall, induced sputum 
is a standardized method and recommendations for sputum 
induction have been formulated by a European Respiratory 
Society/American Thoracic Society task force (Djukanovic 
et al 2002). Induced sputum and its processing do require 
expertise that may be available in specialized centers though 
its use in a primary care setting would be demanding.International Journal of COPD 2008:3(4) 590
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Bronchoalveolar lavage (BAL)
Bronchoalveolar lavage has the advantage of sampling the distal 
airways and alveoli in the lung periphery (Kelly et al 1987). 
However, BAL is more invasive than the above-mentioned 
procedures and has also several other limitations. The invasive-
ness of BAL limits its clinical application in assessing airway 
inﬂ  ammation in asthma and COPD. Generally, BAL has been 
performed safely on patients with stable COPD (Hattotuwa et al 
2002). BAL is, however, risky to patients with moderate/severe 
lung disease, acute exacerbations of airway disease and also 
is unsuitable for children. It is also associated with sedation, 
impaired gas exchange and a risk of infections. Even though 
the BAL technique has also been standardized (Haslam and 
Baughman 1999), BAL ﬂ  uid of COPD patients is often inad-
equate and not representative of the situation in the bronchioles 
due to airway collapse and reduced ﬂ  uid recovery (Barnes et al 
2006). Saline instillation into the lungs can lead to artefacts, ie, 
the dilution of the lavage may contribute to the variability of 
measurements. BAL cannot be recommended for the diagnosis 
or follow-up of the patients with asthma or COPD.
Exhaled markers of oxidant burden 
in asthma and COPD
The markers of oxidant burden that have been generally 
measured from the human lung are shown in Figure 1.
Exhaled nitric oxide metabolites
Elevated FeNO levels have been widely documented in adults 
(Kharitonov et al 1994; Persson et al 1994) and children 
(Lundberg et al 1996; Byrnes et al 1997; Nelson et al 1997) 
with asthma, even in mild and asymptomatic conditions 
(Alving et al 1993; Kharitonov and Barnes 2001b). FeNO 
levels correlate with eosinophilic airway inﬂ  ammation and 
predict a decline in asthma control when repeated as longi-
tudinal measurements (Kharitonov and Barnes 2001a; Liu 
and Thomas 2005; Smith et al 2005). The changes in serial 
FeNO have a higher predictive value than single measure-
ments (Jatakanon et al 2000; Leuppi et al 2001; Kharitonov 
and Barnes 2001a). In addition, the level of FeNO is related to 
several markers of asthma control, such as asthma symptoms, 
dyspnea score, daily use of rescue medication, and revers-
ibility of airﬂ  ow obstruction (Sippel et al 2000). Elevated 
FeNO levels can be detected before one can determine any 
signiﬁ  cant deterioration in airway hyperresponsiveness, 
elevation of sputum eosinophil levels or changes in lung 
function parameters (Kharitonov et al 1996b; Jatakanon 
et al 2000). The main site of origin of the increased levels 
of FeNO in asthma is the lower airways (Kharitonov et al 
1996a). The measurement is highly reproducible both in 
healthy and asthmatic adults and children (Kharitonov et al 
2003). Measurements of exhaled NO at different ﬂ  ows show 
MPO
EPO Nitrotyrosine
4-HNE iNOS
NO
8-IP
ROS
CO
H2O2
Cigarette smoke
Eosinophilic granulocyte
Neutrophilic granulocyte
Macrophage
Figure 1 The markers of oxidative stress are derived from different cells and cell compartments in the alveolar or bronchiolar wall. Neutrophilic granulocytes express myelo-
peroxidase (MPO) and eosinophilic granulocytes are endowed with eosinophilic peroxidase (EPO). Inducible nitric oxide synthase (iNOS) is expressed in the inﬂ  ammatory 
cells and bronchial epithelium. 4-hydroxy-2-nonenal (4-HNE) and 3-nitrotyrosine can be detected in a variety of cell types. Hydrogen peroxide (H2O2), nitric oxide (NO), 
carbon monoxide (CO), and 8-isoprostane (8-iso) represent widely investigated markers in the exhaled air/exhaled breath condensate.International Journal of COPD 2008:3(4) 591
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that the increase in peripheral NO is often related to disease 
severity (Brindicci et al 2005). Overall FeNO is one of the 
most widely used biomarkers in the diagnosis of asthma espe-
cially when the diagnosis is uncertain; recent results clearly 
highlight its beneﬁ  ts also in asthma management.
Exhaled NO is, however, somewhat nonspecific, 
for example the levels are increased in viral infections 
(Kharitonov and Barnes 2001b). On the other hand, FeNO 
levels are generally decreased in smokers (Maziak et al 
1998; Rytila et al 2006). There is also some disagreement 
on whether changes in serial FeNO are signiﬁ  cant evidence 
of loss of asthma control or simply due to errors in measure-
ments or the natural variability of airway inﬂ  ammation over 
time (Kharitonov 2004). This suggests that FeNO may not 
always be related to asthma severity or airway inﬂ  amma-
tion (Kharitonov and Barnes 2000). Development of less 
expensive FeNO analyzers would be beneﬁ  cial, since for now 
FeNO analyzers are available mostly in central/university 
hospitals. Despite these problems, FeNO measurements 
have remained as one of the most important parameters in 
evaluating, treating, and monitoring patients with asthma and 
airway disease with eosinophilic inﬂ  ammation.
In contrast to asthma, the FeNO levels in stable COPD do 
not differ signiﬁ  cantly from controls (Kharitonov and Barnes 
2001b; Rytila et al 2006). FeNO levels increase during 
COPD exacerbation (Maziak et al 1998), most likely due to 
increased oxidative stress especially in cases with coexistent 
asthma and/or the presence of airway eosinophils (Papi et al 
2000). The elevated levels of FeNO in unstable COPD com-
pared both with stable smokers or ex-smokers with COPD 
are attributable to the presence of eosinophils (Maziak et al 
1998). On the other hand, cigarette smoke decreases FeNO 
levels (Kharitonov et al 1995; Robbins et al 1996) by down-
regulating eNOS (Su et al 1998) and consuming NO, making 
FeNO an unreliable marker for the diagnosis of asthma in 
smokers. FeNO has a minor role in evaluating COPD, but 
it may have importance in the differentiation of asthma, 
eosinophilic bronchitis, and COPD.
The reaction of NO and O2
•¯ in the airways leads to 
the formation of peroxynitrite (ONOO) which reacts with 
tyrosine residues of proteins to form a stable product, nitro-
tyrosine. Nitrotyrosine can be detected in EBC, its levels 
are increased in asthma and decreased by corticosteroid 
treatment (Hanazawa et al 2000; Baraldi et al 2006; Bodini 
et al 2006). However, even though both HPLC and GC/MS 
measurements are sensitive and detect similar nitrotyrosine 
levels in the EBC, they do not differentiate healthy controls 
from asthmatics, and therefore nitrotyrosine does not seem 
to be a selective marker for oxidative stress in asthma (Celio 
et al 2006).
Nitric oxide can be trapped by thiol-containing biomol-
ecules (such as GSH) to form S-nitrosothiols. The levels of 
these compounds are elevated in the EBC of smokers and 
in patients with asthma (Corradi et al 2001) and the levels 
decline with corticosteroid treatment in asthma (Kharitonov 
et al 2002). Overall, the increase of the S-nitrosothiols in 
EBC is transitory, and probably not sensitive enough to help 
in the diagnostic assessment of airway diseases. Moreover, 
the levels of NO(x) in EBC appear to be too variable to be 
beneﬁ  cial in clinical investigations (Franklin et al 2006).
Volatile organic compounds
There are many volatile hydrocarbons, but only a few of 
them have been analyzed from exhaled air, with the most 
widely investigated being ethane. Elevated exhaled ethane 
levels have been detected in patients with mild steroid-naïve 
asthma compared with steroid-treated patients and normal 
subjects (Paredi et al 2000a). COPD patients display elevated 
exhaled ethane levels that correlate with the degree of airway 
obstruction (Paredi et al 2000b). Exhaled ethane, however, 
is increased by physical (Leaf et al 1997) and mental stress 
and smoking (Habib et al 1995), probably due to the high 
concentrations of hydrocarbons and direct oxidative damage. 
Cigarette smoke itself contains ethane, and a transient eleva-
tion of exhaled ethane has also been detected in healthy 
smokers (Habib et al 1995). Another hydrocarbon of clinical 
interest is n-pentane and there are some correlations between 
breath pentane and serum biomarkers in smokers. Ethane is 
easier and faster to measure by GC/MS than the other hydro-
carbons, but nonetheless these assays are difﬁ  cult to conduct 
as the analyses require expertise, their measurement is expen-
sive, and the biomarker itself is not speciﬁ  c for any particular 
airway disease. Moreover primary health care centers may 
not have access to a gas chromatograph or the necessary 
skills inherent in this technique. In brief, the measurement 
of ethane is demanding and difﬁ  cult to transfer to clinical 
practice (Larstad et al 2002; Barnes et al 2006). Moreover, 
aldehydes can be detected both in EBC and induced sputum 
but their relative concentrations are different and do not 
correlate with each other (Corradi et al 2004). There are a 
number of other VOCs in addition to ethane; whether their 
combination, ie, VOC “proﬁ  les” can be developed to be 
assayed by modern small gas chromatographic techniques 
would be an interesting area for future research. Recently, 
one technique, so called the electronic nose, in which expi-
ratory vital capacity is collected and then smellprints are International Journal of COPD 2008:3(4) 592
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analyzed by linear discriminant analysis, has been found to 
be a promising method in differentiating exhaled breath of 
patients with asthma from controls even though it appears 
to be less accurate in distinguishing the severity of asthma 
(Dragonieri et al 2007).
Carbon monoxide
Carbon monoxide (CO) is derived from the degradation 
of heme by hemeoxygenase or nonheme-related release 
from xenobiotics and bacteria. Approximately 85% of CO 
is exhaled (Kharitonov and Barnes 2001b; Barnes et al 
2006). Many pathological conditions in addition to airway 
inﬂ  ammation, can contribute to CO formation. One major 
limitation of exhaled CO in assessing oxidative stress in 
asthma or COPD is the marked effects of smoking on CO 
concentrations. The levels of exhaled CO are elevated in 
stable asthma and become reduced towards the normal values 
by administration of inhaled corticosteroids (Zayasu et al 
1997; Horvath et al 1998; Barnes et al 2006). The effects 
of smoking make the assessment of exhaled CO in COPD 
difﬁ  cult. Exhaled CO can be measured by electrochemical 
sensors, laser spectrophotometry, and by an infrared CO 
analysis as well as by gas chromatography, methods that are 
widely available in clinical laboratories. The analysis of CO 
is straightforward but the levels of CO are too variable to be 
signiﬁ  cant in the clinical assessment of asthma and COPD, 
their diagnosis, or follow-up.
Hydrogen peroxide
Exhaled H2O2 has been detected in steroid-naïve asthmatics 
(Kharitonov and Barnes 2002), patients with stable COPD 
and during COPD exacerbation (Dekhuijzen et al 1996; 
Kharitonov 2004) being associated with the disease severity 
(Kostikas et al 2003). Macrophages from healthy smokers 
release more H2O2 than the cells from nonsmokers (Baughman 
et al 1986; Nowak et al 1996; Guatura et al 2000). Exhaled 
H2O2 concentrations are higher in smoking than nonsmoking 
asthmatic patients or controls, though there is extensive vari-
ability (Horvath et al 2004). Acute smoking leads to a further 
elevation in exhaled H2O2 levels in asthmatic patients indicat-
ing that smoking causes an acute additional release of ROS 
in the airways (Horvath et al 2004). Since H2O2 evaporates 
readily due to its highly unstable nature and its concentration 
decreases after a few days of storage at −70 °C, it needs to 
be assayed immediately (van Beurden et al 2002). One study 
claimed that EBC can be stored for up to 40 days without 
any loss of H2O2 concentration (van Beurden et al 2002). 
However, the variability of the H2O2 levels in airway ﬂ  uids 
is high, generally the levels of H2O2 are low and the methods 
for H2O2 analysis are insensitive (Van Hoydonck et al 2004). 
There are different techniques, all with their own limitations 
for H2O2 detection and therefore meaningful comparison 
of the results from various laboratories is difﬁ  cult (Van 
Hoydonck et al 2004). In summary, H2O2 is released from a 
number of cell types, it is relatively unstable, and its analysis 
is not sufﬁ  ciently sensitive or speciﬁ  c to allow the diagnosis, 
differential diagnosis, or monitoring of asthma or COPD.
8-isoprostane
Oxidative damage to lipids leads to the production of isopros-
tanes, which are prostaglandin analogues produced primarily 
by free radical-induced peroxidation of arachidonic acid 
(Morrow et al 1990). 8-iso-prostaglandin F2α (8-isoprostane) 
is the best-characterized isomer, and is considered to be a 
reliable index reﬂ  ecting the degree of oxidative stress in 
vivo. It is a stable metabolite and speciﬁ  c to lipid peroxida-
tion (Janssen 2001; Morrow and Roberts 2002; Cracowski 
et al 2002). It has been proposed to represent an important 
tool for reliably exploring oxidative stress in lung diseases 
(Montuschi et al 2004). Moreover, dietary fats do not have 
any signiﬁ  cant effect on the 8-isoprostane concentration 
(Gopaul et al 2000). Although antioxidants scavenge ROS, 
it seems that they fail to reduce the rate of lipid peroxidation 
(Anderson et al 1988; Habib et al 1999) possibly due to the 
fact that lipid peroxidation is the result of a complicated 
metabolic pathway, where only the ﬁ  rst step is initiated by 
free radicals (Morrow et al 1990). Nevertheless several stud-
ies have indicated that 8-isoprostane may be an important 
mediator of oxidative stress and pulmonary oxygen toxicity 
(Janssen 2001) and form part of a common pathway leading 
to airﬂ  ow obstruction (Paredi et al 2002).
Most studies have used commercial EIA (enzyme 
immunoassay) kits to detect 8-isoprostane in EBC, this 
technique has a good correlation with GC/MS (Montuschi 
et al 1999, 2000; Antczak et al 2002; Kostikas et al 2003; 
Biernacki et al 2003; Baraldi et al 2003a; Van Hoydonck 
et al 2004; Battaglia et al 2005; Simpson et al 2005), 
though there are also dissenting voices (Van Hoydonck 
et al 2004; Rahman 2004; Bodini et al 2004; Simpson 
et al 2005). Elevated EBC 8-isoprostane concentrations 
have been reported in children (Baraldi et al 2003a, 
2003b; Mondino et al 2004; Shahid et al 2005) and 
adults with asthma (Montuschi et al 1999; Antczak et al 
2002; Battaglia et al 2005) and COPD (Montuschi et al 
2000; Kostikas et al 2003; Biernacki et al 2003; Ko et al 
2006). The concentrations increase with asthma severity International Journal of COPD 2008:3(4) 593
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(Montuschi et al 1999; Kharitonov and Barnes 2001b) 
and decline following resolution of acute asthma exacer-
bations, though they still remain higher than in healthy 
individuals (Baraldi et al 2003a). EBC 8-isoprostane 
concentrations decline after allergen avoidance in children 
with allergic asthma (Bodini et al 2004), but are relatively 
resistant to inhaled corticosteroid therapy (Montuschi 
et al 1999; Baraldi et al 2003a, 2003b; Mondino et al 
2004; Shahid et al 2005). The levels do not correlate with 
FeNO (Baraldi et al 2003a) or lung function parameters 
in children with asthma (Baraldi et al 2003b; Shahid et al 
2005). The levels of 8-isoprostane are increased in EBC 
of COPD irrespective of smoking status and lung function 
impairment (Montuschi et al 2000), increasing further dur-
ing exacerbations of COPD, and declining after antibiotic 
treatment (Biernacki et al 2003). Smoking seems to evoke 
an acute 50% increase in EBC 8-isoprostane levels within 
15 minutes (Montuschi et al 2000). The 8-isoprostane 
concentrations in EBC do not correlate with age, sex, or 
history of smoking in pack-years (Montuschi et al 2000). 
No associations have been found between the levels of 
8-isoprostane and dyspnea score, neutrophil count, or lung 
function parameters (Montuschi et al 2000).
There are still major limitations in the detection of 
8-isoprostane in the EBC, the concentrations are variable 
and often remain below the detection limit of the analysis 
(Van Hoydonck et al 2004). These limitations may be partly 
related to the extensive dilution that occurs from water vapour 
during condensation and the low concentrations to be assayed 
that are near the detection limits of the EIA measurements 
(Effros et al 2005). Other confounding factors include 
smoking, diurnal variation, age, alcohol consumption, caf-
feine and possibly also a diet rich in antioxidants. Several 
studies have also clearly revealed extensive variation in the 
levels of 8-isoprostane in nonsmokers and smokers suggest-
ing that the commercial assay itself is variable. Based on the 
earlier and recent studies, it appears that EBC 8-isoprostane 
may not be very sensitive or speciﬁ  c biomarker of oxidative 
stress given the variability in its measurement. The actual 
signiﬁ  cance of 8-isoprostane and its detection methods 
(eg, standardization) in the EBC still await clariﬁ  cation.
Markers of oxidative stress 
in induced sputum
Oxidant-generating enzymes
The most important oxidant-generating enzymes that have 
been assessed in induced sputum specimens include iNOS, 
EPO, and MPO (Kinnula 2005b). The main location of 
iNOS, which is the most efﬁ  cient of the NO synthases in 
producing NO during inﬂ  ammation, is the airway epithelium, 
but it has also been detected in inﬂ  ammatory cells (Barnes 
and Belvisi 1993). Although, the levels of iNOS have been 
found to be elevated in the induced sputum of asthmatics 
(Sugiura et al 2003), variable levels of iNOS have been 
reported in COPD patients (Ichinose et al 2000; Rytila et al 
2006). EPO is elevated in asthma while MPO, which is 
expressed in neutrophils and monocytes (Kim et al 2001), 
is elevated in COPD with the levels being higher in COPD 
than in asthma (Metso et al 2001). A rather similar elevation 
in the number of MPO-positive cells is seen in the induced 
sputum of chronic nonsymptomatic smokers and chronic 
symptomatic smokers with normal lung function, who are 
considered to be at risk of developing COPD (Rytila et al 
2006). Sputum MPO concentrations have been reported to 
be extremely variable in several investigations with large 
standard deviations (Kim et al 2001). However, EPO and 
MPO may possess potential signiﬁ  cance in differentiating 
asthma from COPD. MPO leads to the formation of HOCl 
and EPO to HOBr. These markers still seem to offer the 
greatest potential in the differentiation of asthma and COPD 
but both of them have been evaluated in only a few investi-
gations. In one study, the best results when determining the 
most optimal ﬁ  xation procedure to detect MPO and EPO in 
cytocentrifuged cell samples (induced sputum, BAL) were 
obtained using a commercial reagent Ortho PermeaFix (OPF; 
Ortho Clinical Diagnostics, Raritan, NJ) for ﬂ  ow cytometry 
(Metso et al 2002a). EPO was found to be a useful marker 
for the identiﬁ  cation of eosinophils in sputum and bronchoal-
veolar lavage since anti-EPO antibodies reacted only with 
eosinophils (Metso et al 2002b).
3-nitrotyrosine
The reaction of NO and O2
•¯ in the airways leads to the 
formation of peroxynitrite which reacts with tyrosine 
residues of proteins to form the stable product, nitrotyrosine 
(Ischiropoulos et al 1992). Nitrotyrosine can be formed not 
only by iNOS activation but also by MPO (Davis et al 2001). 
Increased nitrotyrosine immunoreactivity has been reported 
in the lung biopsies of asthmatics (Saleh et al 1998), in EBC 
from asthmatic adults (Hanazawa et al 2000) and children 
(Baraldi et al 2006) as described above and it is associated 
with asthma exacerbation. Nitrotyrosine may play a major 
role in the pathogenesis of airway remodelling, (Kharitonov 
and Barnes 2001b) and it may contribute to airway obstruc-
tion and hyperresponsiveness and epithelial damage in 
asthma (Saleh et al 1998) . Abundant iNOS and nitrotyrosine International Journal of COPD 2008:3(4) 594
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positive sputum cells have also been seen in COPD patients 
compared to healthy smokers with a negative correlation to 
FEV1 (Ichinose et al 2000). However, the sputum samples of 
smokers without airway obstruction and also some samples of 
nonsmokers display increased levels of nitrotyrosine (Rytila 
et al 2006). It is likely that nitrotyrosine is not speciﬁ  c in 
differentiating between asthmatic and cigarette smoke-related 
airway disease.
8-isoprostane
Recent evidence suggests that sputum 8-isoprostane mirrors 
airway oxidative stress and is related to respiratory disease 
type pattern and activity (Wood et al 2005). The level of 
8-isoprostane is higher in sputum than in EBC (Simpson et al 
2005). Sputum 8-isoprostane is higher in adults with stable 
asthma than in healthy subjects, increase further with disease 
severity and decrease signiﬁ  cantly after treatment of acute 
asthma exacerbation, although there is a wide variability 
in the 8-isoprostane concentrations between and within the 
groups (Wood et al 2005). Moreover, a recent study could 
not detect any difference between sputum 8-isoprostane 
levels in mild asthmatics and healthy controls (Louhelainen 
et al 2008). Sputum 8-isoprostane levels are elevated in 
COPD and cigarette smokers, but do not clearly differentiate 
healthy smokers from symptomatic smokers, ie, those who 
are at risk for developing COPD (Kinnula et al 2007). No 
longitudinal studies have been conducted with this marker, 
making it difﬁ  cult to draw any ﬁ  nal conclusions about its real 
signiﬁ  cance. As described above, the major problems with 
this marker include the poor sensitivity, speciﬁ  city and the 
fact that commercial EIA method and/or the impurities of the 
samples may contribute to its levels in sputum specimens.
4-hydroxy-2-nonenal
Aldehydes generated endogenously during lipid peroxidation 
may be involved in many pathophysiologic events associated 
with oxidative stress in cells and tissues (Gutteridge 1995). 
4-HNE is a highly reactive and diffusible end-product of 
oxidative stress-induced lipid peroxidation that can attack 
targets far from the original site of free radical generation 
(Esterbauer et al 1991). It is hypothesized that the degree 
of formation of 4-HNE in response to smoking may also 
contribute to the development of enhanced airspace inﬂ  am-
mation in COPD (Rahman et al 2002). 4-HNE can be 
detected in lung biopsies of COPD patients (Rahman et al 
2002), but recently it has also been detected in induced 
sputum samples of chronic smokers, irrespective of the lung 
function parameters or symptoms compared to nonsmokers 
(Rytila et al 2006). These results suggest that even though 
4-HNE conﬁ  rms that oxidative damage has occurred, it may 
not provide speciﬁ  c insight into the pathogenesis of the airway 
disease, and may not be a sensitive biomarker for assessing 
the disease severity.
Antioxidants and antioxidant enzymes
The oxidant/antioxidant equilibrium is disturbed in asthmatic 
and COPD patients not only due to the chronic inﬂ  ammation, 
activation of inﬂ  ammatory cells and/or oxidant producing 
enzymes but also due to changes in the antioxidant defense 
of the lung. It is believed that the major low molecular weight 
antioxidant of human airway secretions is GSH (Cantin et al 
1987) but how well its levels are maintained in the ELF is 
still poorly understood. In addition to free GSH, a major 
proportion of GSH is bound to proteins and this fraction 
is difﬁ  cult to measure. GSH has been investigated both in 
airway secretions and BAL but it has been shown to be neither 
sensitive nor speciﬁ  c for asthma or COPD.
The ﬁ  rst line of defense enzymes against superoxide 
radicals involves superoxide dismutases (SOD) such as 
MnSOD and there are suggestions that MnSOD may become 
inactivated in the airways of asthma patients (Comhair et al 
2005). Enzymes related to GSH synthesis/homeostasis such 
as glutathione peroxidases (GPx) play an important role in 
the antioxidant defense of human lung (Cantin et al 1987). 
Extracellular glutathione peroxidase (eGPx) has not been 
investigated in sputum specimens but it is increased in the 
BALF of asthma patients (Comhair et al 2001). Glutare-
doxins (GRX) participate in GSH binding to proteins and 
thiol oxidation/reduction, reactions that regulate the active 
forms of many thiol containing enzymes. GRX-1 is mainly 
expressed by macrophages (Peltoniemi et al 2004) and the 
levels are decreased in the sputum macrophages of COPD 
patients (Peltoniemi et al 2006). Glutathione-S-transferase 
omega, which has many functional features in common with 
GRX, has been recently found to be expressed mainly in 
alveolar macrophages, and similar to GRX-1, its levels also 
decline in COPD (Harju et al 2007). Catalase is expressed 
both in the inﬂ  ammatory cells and alveolar epithelium, and it 
is inactivated at least in the murine model of asthma (Ghosh 
et al 2006). Heme oxygenase 1 (HO-1) is an enzyme induced 
by oxidant stress (stress-response protein) and cytokines. It is 
expressed mainly in alveolar macrophages of human lung and 
macrophages of induced sputum of steroid-naïve asthmatics 
show prominent but only transient HO-I immunoreactivity. 
This is not seen in asthmatics treated with corticosteroids 
(Harju et al 2002b). The expression of HO-1 is increased International Journal of COPD 2008:3(4) 595
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also in the sputum macrophages of COPD patients compared 
to healthy nonsmokers, but there is no difference between 
COPD patients and healthy smokers (Maestrelli et al 2001). 
Cigarette smoking increases especially the RNA expres-
sion of GSH-related enzymes in the bronchial brushings of 
healthy individuals (Hackett et al 2003), but the RNA levels 
of antioxidant enzymes in the bronchial epithelium have high 
variability in COPD depending on its severity (Pierrou et al 
2007). Even though the above mentioned ﬁ  ndings have not 
been conﬁ  rmed in sputum, the results are interesting; they 
suggest that combined proﬁ  les of antioxidant and detoxi-
ﬁ  cation enzymes and their posttranslational modiﬁ  cations 
(such as oxidation, thiolation, S-nitrosylation) may be 
promising indicators of the severity of oxidative stress in 
human airways.
Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are a large family of 
proteolytic enzymes (over 30 MMPs have been character-
ized) that degrade the components of the extracellular matrix 
(Ohbayashi 2002). These enzymes are involved in the pul-
monary remodelling processes that underpin both asthma and 
COPD (Parks and Shapiro 2001; Kelly and Jarjour 2003). 
Oxidative stress, mainly cigarette smoke associated oxidants, 
may be one of the major factors contributing to MMP activa-
tion. MMPs can be readily detected in sputum specimens. 
There are signiﬁ  cant differences in the MMP proﬁ  les in 
COPD and asthma. In COPD, elevated levels of MMP−1, 
−8, and −9 compared with asthmatics, nonsmokers, and non-
symptomatic cigarette smokers have been reported, and these 
changes may also reﬂ  ect the different pathogenesis of these 
diseases (Culpitt et al 2005). In the future, MMPs may be 
considered as additional biomarkers in COPD and/or asthma 
development. These markers also hold potential in evaluating 
COPD phenotypes, since the emphysematous type of COPD 
would be predicted to exhibit a different proﬁ  le of MMPs 
than the disease where there is airway predominance.
Oxidant markers in bronchoalveolar 
lavage
The total BAL cell proﬁ  le and also the cell count differ 
in asthma and COPD. The number of inﬂ  ammatory cells, 
especially neutrophils, are higher in COPD patients suf-
fering exacerbations compared with stable COPD patients 
or healthy controls (Drost et al 2005). BAL ﬂ  uid has been 
widely used for the assessment of inﬂ  ammatory cytokines 
such as interleukin-8 (IL-8) and tumor necrosis factor 
alpha (TNFα) in asthma and COPD (Aaron et al 2001; 
Drost et al 2005). The most widely investigated marker of 
oxidant/antioxidant balance in BAL ﬂ  uid is GSH, the levels 
of which are increased in smokers and patients with stable 
COPD compared to the nonsmokers, but reduced during 
exacerbations as compared to the levels found in stable 
COPD (Drost et al 2005). On the other hand, older smokers 
with a long-term smoking history exhibit elevated oxidized 
glutathione (GSSG) and protein carbonyls in their BAL 
ﬂ  uid even in the absence of any lung disease, indicating 
that lung antioxidant defences have become overwhelmed 
the prolonged exposure to the noxious substances present in 
cigarette smoke (Nagai et al 2006). 8-isoprostane and some 
other oxidant markers have been compared between EBC 
and BAL, but clinical disease markers of inﬂ  ammation and 
oxidative stress in EBC and BAL do not correlate with each 
other (Jackson et al 2007). Thus, even though some markers 
in BAL ﬂ  uid may seem to offer promise in the assessment of 
inﬂ  ammation, BAL is too invasive and not sensitive enough 
to be of use in the assessment of oxidative stress/airway 
inﬂ  ammation in clinical practice.
Pitfalls in measuring ROS
in smoking asthmatics
One problem in assessing the importance of oxidant-related 
biomarkers, for example FeNO and 8-isoprostane, is that 
smoking per se has signiﬁ  cant effects on the levels of these 
markers, and this phenomenon is especially important in 
asthma. The prevalence of active cigarette smoking among 
asthmatics is as common as it is in the general population, 
for example in Finland as many as 30% of asthmatics are 
smokers (Haahtela et al 2006). There is limited data on the 
airway pathology of smoking asthmatics, since these patients 
are frequently excluded from experimental studies. Asthma 
and cigarette smoking potentiate the effects of each other, 
leading to impaired asthma control, more severe symptoms 
(Althuis et al 1999), increased need for rescue medication 
(Gallefoss and Bakke 2003), accelerated deterioration of lung 
function (Lange et al 1998) and reduced short-term thera-
peutic response to corticosteroids (Chaudhuri et al 2003). 
Smoking may also modify the typical asthmatic inﬂ  ammation 
proﬁ  le, which complicates the differential diagnosis from 
COPD. It also appears that there are features of both acceler-
ated and suppressed inﬂ  ammatory responses in smokers with 
asthma. The number of eosinophils in sputum are decreased 
(Chalmers et al 2001), perhaps due to the exogenous NO in 
cigarette smoke increasing apoptosis of activated eosinophils 
(Assreuy et al 1993) whereas the number of neutrophils is 
elevated (Chalmers et al 2001). Many asthmatic smokers International Journal of COPD 2008:3(4) 596
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have mixed features of typical asthmatic and smoke-related 
airway inﬂ  ammation and pathology. Results from clinical 
studies suggest that smokers with asthma may be resistant 
to therapeutic effects of the corticosteroids (Chalmers et al 
2001; Chaudhuri et al 2003). There is also evidence that the 
time of initiation of smoking may inﬂ  uence the asthma phe-
notype: atopy-associated asthma has been shown to develop 
before smoking initiation (Raherison et al 2003). It has 
been claimed that the remodeling of airways might be more 
severe in asthmatic smokers (Carroll et al 2000). Several 
markers of oxidative/nitrosative stress are increased even 
in “healthy” smokers, but we are not aware of any studies 
where the oxidant markers have been compared between 
healthy smokers and smoking asthmatics. It is apparent that 
the sensitivity of FeNO to detect a worsening of asthmatic 
inﬂ  ammation in smokers is poor, since smoking on its own 
decreases FeNO levels signiﬁ  cantly.
Disease progression, COPD 
phenotypes, and oxidative stress
The evaluation of oxidative stress in disease progression is 
especially complex in COPD. The symptoms do not closely 
reﬂ  ect spirometric changes and the symptoms may predict 
exacerbation only in some individuals (Seemungal et al 
2000). COPD exacerbations in turn are important events 
in terms of disease progression, morbidity, and mortality. 
Many patients with COPD never recover completely from 
the exacerbation. The lung pathology is especially complex 
in COPD as the disease contains many phenotypes displaying 
a wide variety of airway and emphysematous changes. How-
ever, all phenotypes are treated similarly, because there are 
no speciﬁ  c biomarkers for the differentiation of the disease 
subtypes or their progression. At present, no biomarker in 
clinical practice is able to differentiate small airway inﬂ  am-
mation and ﬁ  brosis from alveolar destruction even though 
these changes are the main pathophysiologic events in 
COPD (Barnes et al 2006). Special efforts should be directed 
towards ﬁ  nding reliable biomarkers that would differentiate 
the phenotypes of COPD in addition to identifying markers 
that can be used in the assessment of disease progression. 
Though outside the scope of this review, which concentrates 
on local airway biomarkers, a number of biomarkers in the 
circulating blood/ plasma and in the skeletal muscle are under 
intensive investigation as ways of monitoring the progression 
of COPD (Aldonyte et al 2004; Gosker et al 2005; Hurst et al 
2006; Jones and Agusti 2006).
Several studies have highlighted the usefulness of 
8-isoprostane in the evaluation of oxidative stress in COPD 
and during COPD exacerbations. This agent is known to 
exert biological activity such as evoking the contraction of 
human bronchial smooth muscle in vitro (Paredi et al 2002), 
and being able to elicit airway hyperresponsiveness (Held and 
Uhlig 2000) and evoke airway obstruction and plasma exuda-
tion (Okazawa et al 1997), evidence that it may be involved 
in the pathophysiology and progression of COPD. Many 
cross-sectional studies have shown that 8-isoprostane levels 
correlate with lung function parameters, but these ﬁ  ndings 
have not been conﬁ  rmed in longitudinal investigations. As far 
as we are aware there are no studies to explain how elevated 
8-isoprostane levels are associated with COPD phenotypes, 
respond to treatment in COPD, or whether 8-isoprostane can 
be used in the follow-up of these patients.
Several markers of oxidant burden have been suggested 
to associate both with the pathogenesis and disease pro-
gression of asthma (Barnes 1990) and COPD (Repine et al 
1997). Considering the complexity of oxidative stress and 
the inﬂ  ammatory cascade and the interaction between these 
two processes, it is, however, unlikely that measurement of 
any single molecule in the EBC, sputum, or in biological 
ﬂ  uids would be able to provide adequate information about 
disease progression. Potential current markers that could 
possibly be used for the assessment of the disease severity or 
progression include the combination of several markers such 
as EBC VOC proﬁ  les with small detectors, FeNO, sputum 
oxidant markers, speciﬁ  c MMPs, and selected antioxidant 
enzymes.
Antioxidant therapies and disease 
progression
Since it seems likely that asthma and COPD are associated 
with an elevated oxidant burden, these diseases might be 
treated with exogenous antioxidants or related strategies. It 
is likely that vitamins taken orally do not reach the critically 
damaged areas of the lung, which has its own highly speciﬁ  c 
antioxidant systems. Several attempts have been made to 
improve GSH homeostasis by treatment with inhaled and 
oral GSH, since the level of GSH is much higher in the 
epithelial lining ﬂ  uid than in any other organ or circulating 
blood, and decreased by oxidative stress. However, GSH 
is poorly absorbed through membranes and inhaled GSH 
itself has been shown to cause bronchoconstriction (Rah-
man and MacNee 1999). N-acetyl-L-cysteine (NAC) may 
improve GSH balance but this compound is known to also 
possess GSH-independent pro-oxidant effects at the cellular 
level. NAC has been tested and administered by inhalation, 
orally and intravenously (Rahman and MacNee 1999). International Journal of COPD 2008:3(4) 597
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Oral NAC has been shown to decrease the risk for COPD 
re-hospitalisations (Gerrits et al 2003) and to decrease H2O2 
levels in the exhaled air in COPD (Kasielski and Nowak 
2001), but the results of the multicenter BRONCUS-trial 
revealed no major effects on lung function values or COPD 
exacerbations (Dekhuijzen 2004; Decramer et al 2005). 
A recent systematic review on NAC indicated that the use 
of NAC could signiﬁ  cantly reduce the odds of exacerbation 
in patients with COPD (Sutherland et al 2006) and therefore 
could possibly have effects on disease progression. Whether 
the new antioxidant mimetics that are under development 
will have beneﬁ  ts in asthma or COPD will be an interesting 
area of future investigation.
Perspective/conclusions
The assessment of noninvasive biomarkers in asthma and 
COPD is an area of intensive investigation. Noninvasive 
specimens that reﬂ  ect oxidative stress in the airways include 
exhaled air, EBC, and induced sputum. Induced sputum is 
a widely used technique and there are many advantages 
in using induced sputum both in asthma and COPD. One 
practical problem with induced sputum, however, is the 
fact that it is not totally noninvasive and sample processing 
requires expertise. Nonetheless, induced sputum is promis-
ing especially for the analysis of markers with different roles 
in the pathogenesis of asthma and COPD. One example is 
the differentiation of the subphenotypes (either airway or 
emphysema predominance) of COPD by combining the 
existent knowledge of oxidant markers in the sputum speci-
mens and expanding the methodology to new technologies 
including proteomics (sputome).
Exhaled air and EBC are totally noninvasive and there-
fore most interesting for the clinical evaluation of airway 
diseases, their differential diagnosis and progression. FeNO 
has been the most widely used of the various markers and 
has been shown to have clinical signiﬁ  cance in asthma, its 
differential diagnosis and monitoring (Table 1). Further 
emphasis should be directed in the development of small, 
easy-to-handle, portable devices for the investigation of the 
exhaled gas proﬁ  les (such as VOCs) and their role especially 
in COPD. Real time analysis of volatile organic molecules 
by infrared laser spectroscopy enables online measurement 
of oxidative markers (Murtz et al 1999) and these techniques 
offer the potential for real time monitoring of EBC also in 
asthma and COPD. Metabolomic analysis (quantitative 
measurement of the dynamic multiparametric metabolic 
response of living systems to pathophysiological stimuli or 
genetic modiﬁ  cation) (Nicholson et al 1999) can provide 
new biochemical proﬁ  les for the assessment of low molecu-
lar weight metabolites in EBC. These methods include 
nuclear magnetic resonance (NMR) and allow simultane-
ous detection of hundreds of low molecular weight species 
within a single ﬂ  uid sample. These NMR “ﬁ  ngerprints” may 
further improve the characterization of the speciﬁ  c features 
in asthma and COPD and their differentiation (Carraro et al 
2007). Lipidomics has been evaluated in vitro and in the 
developing lung (Postle et al 2006; Bernhard et al 2007), 
but its value in asthma and COPD remains to be conﬁ  rmed 
in the future.
Many investigations have used sophisticated techniques 
such as microarray or proteomics which generate enormous 
amounts of information that is difﬁ  cult to interpret even 
Table 1 The principal noninvasive methods in assessing airway inﬂ  ammation and oxidative stress from patients with known or suspected obstruc-
tive pulmonary disease. The list includes some markers that already are in clinical use as well as several markers in experimental use
Specimens Advantages Disadvantages Markers
Exhaled air Noninvasiveness, useful for 
children, follow up of asthmatic 
inﬂ  ammation 
Minor signiﬁ  cance in COPD, FeNO, ethane, H2O2, CO
Exhaled breath condensate Noninvasiveness, useful for 
children
Problems with sample dilution, 
lack of standardization and 
speciﬁ  city
H2O2, 8-isoprostane, cytokines,
Induced sputum Informative; inﬂ  ammatory cell 
proﬁ  le
Can cause inﬂ  ammation/
bronchoconstiction, requirements 
for laboratory standards
Inﬂ  ammatory cells. EPO, ECP, 
MPO, iNOS, Nitro-tyrosine, 
8-isoprostane, 4-HNE, MMPs
Bronchoalveolar lavage ﬂ  uid Accurate, standardized method Invasiveness. Information is 
obtained only from the alveolar 
level 
Inﬂ  ammatory cells and 
selected cytokines, GSH, 
MMPs
Notes: The best potential current markers in the differential diagnosis of asthma and COPD are underlined. Among all oxidant markers FeNO is widely used in clinical practice.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeNO, fractional exhaled nitric oxide; CO, carbon monoxide; H2O2, hydrogen peroxide; iNOS, inducible nitric oxide 
synthase; EPO, eosinophilic peroxidase; ECP, eosinophilic cationic protein; MPO, myeloperoxidase; 4-HNE, 4-hydroxy-2-nonenal; MMPs, matrix metalloproteinases; GSH, glutathione.International Journal of COPD 2008:3(4) 598
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by the investigators. It is clearly challenging to extrapolate 
these results from a speciﬁ  c cell type (for example bronchial 
epithelial cells obtained by bronchial brushing) or from total 
lung homogenate to a noninvasive specimen such as exhaled 
air or sputum. It is likely that proteomics offers multiple 
advantages compared to the gene expression studies since 
proteins and not genes ultimately determine cellular func-
tion (Raj et al 2007). Proteomic studies have also revealed a 
total of nearly 200 human proteins from the induced sputum 
specimens (sputome) (Nicholas et al 2006; Casado et al 2007) 
and these proﬁ  les may differ in various airway diseases and 
phenotypes (Casado et al 2007). Recent studies have also dis-
covered panels/clusters of oxidant/antioxidant enzymes that 
may be utilized for the assessment of disease severity. Over-
production of ROS can also cause oxidative modiﬁ  cations of 
several important antioxidant/defense enzymes, which may 
Verification of novel markers
Exhaled air
profiles
Identification
of novel markers
Proteomics
Bronchoalveolar
lavage
Bronchial brushings
Tramsbronchial
biopsy /VATS
EBC
Induced
sputum
Blood/serum
Microarray,
Genome Screening
Figure 2 Future strategies for the discovery of new biomarkers in asthma and COPD, their diagnosis, differential diagnosis and assessment of the COPD phenotypes. The 
methods include microarray and proteomics combined with novel technologies. In these studies, protein expression has multiple advantages compared to gene expression, 
since proteins and not genes ﬁ  nally determine cellular function. Methods such as metabolomics (analysis of low molecular weight molecules from exhaled breath condensate), 
lipodomics and sputome (proteomics from induced sputum) have been evaluated and are ready for clinical prospective studies in asthma and COPD. Microarray/proteomics 
obtained from lung tissue, bronchial brushings and/or bronchoalveolar lavage have been conducted in asthma and/or COPD, and their extrapolation to noninvasive samples 
is being investigated in many laboratories.
Table 2 Potential noninvasive oxidant biomarkers for the assessment 
of asthma, COPD, their differential diagnosis and phenotypes by 
combining the existent knowledge and future technologies
Exhaled air/exhaled breath condensate (EBC)
 •    FeNO (various ﬂ  ow rates)
 •      Proﬁ  les/clusters of volatile compounds by using new gas 
chromatographic/MS technologies
 •      Metabolomics (Assessment of low molecular weight compounds 
in EBC)
Induced sputum
 •      Combinations of certain oxidant markers and footprints of oxida-
tive damage (differential diagnosis, disease severity)
 •    Combinations of certain antioxidant enzymes (disease severity)
 •      Posttranslational modiﬁ  cations/inactivation of the antioxidant/
detoxiﬁ  cation enzymes in human lung (disease severity)
 •      Matrix metalloproteinases and their speciﬁ  c combinations (disease 
severity, differential diagnosis, phenotype)
 •      Sputome (proteomics from induced sputum) (differential diagnosis, 
disease severity, phenotype)International Journal of COPD 2008:3(4) 599
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be associated with alterations in enzyme conformation and 
thus they can function as markers of the degree of oxidative 
stress present in the airways. These changes that currently 
can be analyzed by 2DE electrophoresis and MS but in the 
future new potent nongel-based proteomic methods may 
represent the next generation of more speciﬁ  c biomarkers 
both for asthma and COPD. In view of the overlapping pat-
terns of the proﬁ  les of various oxidant biomarkers in asthma 
and COPD, the utilization of very sophisticated techniques 
in their assessment is important. Since cigarette smoking is 
inevitably related to COPD and since smoking only partly 
overlaps with the pathophysiology of asthma, new tools 
might offer an easier and cost-effective way for early diag-
nosis and differentiation of asthma and COPD. The future 
directions in the search for potential markers of oxidant 
burden are summarized in Table 2 and Figure 2.
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